Overview

* Company reported a net loss of $28.7 mln for Q3 2025

Result Drivers

* Research and development expenses were $19.2 million for the three months ended September 30, 2025 compared to $18.0 million for the three months ended September 30, 2024.

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$28.71

Income mln

Q3 Basic -$0.20

EPS

Q3 $30.53

Operatin mln

g

Expenses

Q3 -$30.15

Operatin mln

g Income

Q3 -$28.60

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Absci Corp ( ABSI ) is $8.00, about 56.9% above its November 11 closing price of $3.45

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)